Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alprostadil topical - VIVUS

Drug Profile

Alprostadil topical - VIVUS

Alternative Names: ALISTA; Prostaglandin E1 topical - VIVUS

Latest Information Update: 10 Jun 2009

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator VIVUS
  • Developer AndroSolutions; Asivi; VIVUS
  • Class Erectile dysfunction therapies; Monounsaturated fatty acids; Muscle relaxants; Peripheral vasodilators; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin E1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Female sexual dysfunction

Most Recent Events

  • 10 Jun 2009 Discontinued - Phase-II for Female sexual dysfunction in USA (Topical)
  • 03 Oct 2006 Final results from a phase IIb clinical trial in patients with Female sexual arousal disorder have been added to the Women's Health therapeutic trials section
  • 07 Dec 2005 VIVUS has completed enrolment in the phase IIb trial for Female sexual dysfunction in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top